Hims Adds Testosterone Options, With Key Questions for Veterans

On October 21, 2026, Hims & Hers announced new injectable and oral options for its Hims testosterone program. The company described a compounded injection, generic testosterone cypionate and FDA-approved oral Kyzatrex. According to its announcement and launch coverage from Investing.com, these choices expand an existing program that includes enclomiphene.

For active personnel and veterans comparing testosterone services, the practical issue is not simply which delivery method looks most convenient. It is how the exact product fits an individual clinical assessment, what its regulatory status means and how treatment will be monitored.

The expansion adds choices rather than a new clinical standard

Hims’ announcement changes the options described within its commercial program. It does not establish a new diagnostic standard or a reason to choose testosterone therapy based on physical performance goals alone. A product launch and a clinical recommendation answer different questions.

BattleVet connects hormone health with strength, recovery and healthy aging. From that perspective, the useful question is whether an option supports an appropriate long-term health decision rather than whether it is easier to obtain. Convenience belongs in that discussion without becoming the deciding factor.

The evidence has clear boundaries. This is a company-reported business update rather than an independent comparison of treatment outcomes or market use. The reviewed reporting does not establish a connection to military or VA programs or specific benefits for service members. Hims also does not define eligibility criteria for its compounded injectable in the announcement.

Those distinctions matter when evaluating a commercial health service. BattleVet’s resource on assessing medical claims and treatment evidence provides a broader framework for separating an announcement from evidence that should guide a personal care decision.

The product descriptions need to remain distinct

The company’s descriptions identify different formulations and regulatory categories. They should remain separate when discussing the launch. Describing the entire expansion as FDA-approved would go beyond the specific wording attached to oral Kyzatrex.

The compounded injection requires a product-specific discussion

Hims describes a compounded injectable option for eligible patients. The relevant discussion is therefore about that exact formulation and the basis for offering it to a particular patient.

Useful questions include what product would be prescribed and how its regulatory status is explained. The company’s statement that prescribing occurs only when medically appropriate describes its intended process. It does not replace a qualified clinician’s assessment of the individual considering treatment.

Generic testosterone cypionate is a separate offering

The announcement also identifies generic testosterone cypionate. That description should not be treated as another name for the compounded option or merged with the description of oral Kyzatrex.

For someone comparing services, the practical task is to identify the exact medicine under consideration. A general discussion of “testosterone injections” leaves out distinctions that may matter to the prescribing decision. The product name and formulation belong in the conversation before convenience becomes the focus.

FDA-approved oral Kyzatrex has its own status

Hims describes Kyzatrex as an FDA-approved oral option. That approval description belongs to this product rather than automatically extending to every treatment offered through the program.

Oral delivery may be an important preference for someone comparing options. It still does not settle whether that medicine is appropriate for the person considering it. The launch supports a discussion about an additional delivery choice, not a conclusion that oral treatment is preferable to an injectable option.

Testing and follow-up remain central to the decision

According to the company announcement and Investing.com’s launch coverage, the service includes intake, at-home blood collection and provider review. Prescribing is described as occurring when appropriate. Hims says patients who start treatment receive follow-up assessments and laboratory testing, with care adjusted over time.

This pathway makes provider review and continued assessment part of the company’s stated service. It should not be reduced to a home test followed by a preferred product. The clinical discussion needs to connect the assessment with the reason for treatment and the plan for reviewing it.

For a patient comparing care arrangements, the useful questions concern how those stages connect. Who reviews the results? How is the treatment decision explained? What does the follow-up process involve once a prescription has been started?

These are questions about care quality and continuity rather than requests for a particular prescription. The announcement offers a starting point for that conversation without supplying an individualized testing or monitoring plan.

Fertility belongs in the discussion before treatment

In coverage of the launch, urologist Mohit Khera described telehealth TRT services as potentially promising for access “as long as it’s monitored appropriately.” He also cautioned that testosterone therapy can impair fertility. His comments concern telehealth TRT generally rather than findings about Hims’ specific products or care process.

That makes fertility goals part of the treatment discussion rather than a detail to address after choosing a delivery method. A person considering therapy may place different weight on family planning than on the convenience of a particular formulation.

The appropriate response is a conversation with a qualified clinician about those goals and the proposed treatment. It is not to assume that choosing an oral product instead of an injection resolves the concern. The key issue remains the therapy being considered and its fit with the individual’s priorities.

The update sharpens the questions to take into care

The practical change is a broader set of commercial choices. The guidance reinforced by the announcement is to evaluate those choices through diagnosis, product identity, monitoring and fertility goals.

A focused clinical discussion can cover the following:

• The reason for treatment. What findings support the proposed diagnosis and treatment decision? The discussion should explain why therapy is being considered rather than beginning with a preferred delivery method.
• The exact formulation. Which medicine would be prescribed? Its name and formulation should be clear enough to distinguish it from the other options in the announcement.
• The regulatory description. How does the clinician explain the status of that specific product? A description attached to one option should not be assumed to cover the others.
• The follow-up plan. How will assessments and laboratory testing inform continued care? Hims describes ongoing review, so the details of that review are relevant to comparing the service.
• Fertility goals. How do current or future family plans affect the discussion? Khera’s caution makes this a substantive part of evaluating TRT.

These questions are a framework for informed discussion rather than a self-directed treatment protocol. Personal decisions about diagnosis or prescribing belong with qualified care.

Veterans looking at hormone health in a wider context can also read about hormonal health across life after service. For active personnel, BattleVet’s coverage of military hormone-health policy and performance expectations addresses a separate part of the broader topic. Neither context should be replaced by a commercial product comparison.

Future research should connect access with meaningful outcomes

The next useful evidence would connect access to clearly reported care processes and patient outcomes. For a military and veteran audience, that also means understanding whether findings apply to the people receiving care rather than assuming that a broader commercial menu answers their needs.

As telehealth testosterone services add more formulations, will future research show how product selection and ongoing monitoring affect long-term health outcomes for veterans?

Sources

1. A new era for testosterone care hims launches new injectable and oral trt options
2. Hims expands testosterone treatment options with new products By Investing.com
3. Telehealth Giant Hims Wants to Test Every Dude for Low Testosterone